v3.26.1
SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION
13. SEGMENT INFORMATION
We operate in a single segment dedicated to the discovery, development, manufacturing and commercialization of RNAi therapeutics. Consistent with our management reporting, results of our operations are reported on a consolidated basis for purposes of segment reporting. Our Chief Executive Officer, or CEO, as the chief operating decision maker, or CODM, evaluates performance and decides how to allocate resources based on consolidated net income (loss) that is reported on the condensed consolidated statements of operations and comprehensive income (loss). The measure of segment assets is reported on the condensed consolidated balance sheets as total assets. Please refer to the condensed consolidated financial statements for further information related to these measures of segment performance. In addition, research and development and selling, general and administrative expenses are significant segment expenses regularly provided to the CEO with the following categories:
Research and Development
Three Months Ended
June 30,		Six Months Ended
June 30,
(In thousands)
2026202520262025
Clinical research and outside services$244,226 $140,692 $443,483 $268,035 
Compensation and related125,390 143,450 249,688 242,637 
Occupancy and all other costs(1)
43,518 39,479 84,829 78,071 
Total research and development expense
$413,134 $323,621 $778,000 $588,743 
Selling, General and Administrative
Three Months Ended
June 30,		Six Months Ended
June 30,
(In thousands)
2026202520262025
Compensation and related
$166,619 $191,233 $329,696 $322,670 
Consulting and professional services
120,721 82,637 225,898 147,324 
Occupancy and all other costs(1)
60,582 49,444 114,879 93,269 
Total selling, general and administrative expense
$347,922 $323,314 $670,473 $563,263 
(1) Occupancy and all other costs includes facilities, information technology, depreciation and certain departmental expenses.